|[January 22, 2013]
McCullough Joins Atherotech Diagnostics Lab's Medical Advisory Board
BIRMINGHAM, Ala. --(Business Wire)--
Diagnostics Lab recently appointed cardiology expert and
prolific researcher Peter A. McCullough, M.D., M.P.H., F.A.C.C.,
F.A.C.P., F.C.C.P., F.A.H.A., F.N.K.F., to its Medical Advisory Board.
With over 800 published, scientific communications, McCullough is an
internationally recognized authority on the role of chronic kidney
disease as a cardiovascular risk state. As a member of the Medical
Advisory Board, he will counsel Atherotech in the expansion of its
proprietary test portfolio and guide scientific research using the
company's patented VAP®
(Vertical Auto Profile) Lipid Panel. Atherotech's Medical Advisory
Board includes highly regarded physicians who bring expertise in current
trends in cardiovascular disease identification, risk assessment and
management, and research and outcome studies. To review individual,
detailed biographies, please visit www.Atherotech.com/mad.
"Peter is a luminary in the field of cardiology and believes in the
power of our VAP technology as the future of cardiovascular risk
assessment," CEO Michael Mullen said. "He is a welcome addition to our
Medical Advisory Board, and we're proud to partner with hm."
McCullough's cardiodiagnostic experience includes playing an integral
role in developing the BNP (B-type natriuretic peptide) assessment, a
blood test that helps clinicians evaluate complex cardiac functions. He
is currently Chief Academic and Scientific Officer at St. John
Providence Health System in Warren, Mich., where he oversees graduate
medical education, corporate medical staff services, and research.
McCullough is the current Chair of the National Kidney Foundation's
Kidney Early Evaluation Program, the nation's largest community
screening effort for chronic diseases. He is the co-editor of Reviews
in Cardiovascular Medicine and serves on the editorial boards of
multiple specialty journals. He has led numerous clinical trial
steering, data safety monitoring, and events committees, and has
testified before the U.S. Food and Drug Administration and the
Congressional Oversight Panel.
For information on Atherotech Diagnostics Lab, visit www.Atherotech.com
or call 877-901-8510. Health care professionals interested in real cases
from the trenches of lipidology may visit www.CobblesCorner.com,
Atherotech's official blog. Atherotech is on Twitter (News - Alert) at www.Twitter.com/Atherotech,
on Facebook (News - Alert) at www.Facebook.com/Atherotech,
and broadcasting at www.YouTube.com/user/VAPatherotech.
About Atherotech Diagnostics Lab & the VAP Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory
specializing in cardiometabolic testing and disease management
solutions. Atherotech's proprietary and comprehensive VAP®
Lipid Panel enables clinicians to accurately stratify a patient's
cardiovascular risk and deliver personalized treatment strategies to
improve health outcomes. The Vertical Auto Profile (VAP) technology
reveals residual cardiometabolic risk as recommended in the NCEP ATP (News - Alert)
III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel
utilizes direct measurement to identify cholesterol, triglyceride and
genetic lipid disorders. The company's dedication to affordable,
comprehensive disease management solutions includes Our Healthy HeartTM,
a patient consultation program and expert lipid management education
service to health care providers. For more information, please visit www.Atherotech.com
or call 1-866-VAP-TEST.
[ Back To TMCnet.com's Homepage ]